6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens
Lanreotide
Lanreotide 120mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 60mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Lanreotide 90mg/0.5ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
| Endocrine system | Neuroendocrine tumours |
Pegvisomant
Pegvisomant 10mg powder and solvent for solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
Pegvisomant 15mg powder and solvent for solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
Pegvisomant 20mg powder and solvent for solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
Pegvisomant 30mg powder and solvent for solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Acromegaly |
Somatropin
Norditropin FlexPro 10mg/1.5ml solution for injection pre-filled pens
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Norditropin FlexPro 15mg/1.5ml solution for injection pre-filled pens
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Norditropin FlexPro 5mg/1.5ml solution for injection pre-filled pens
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Omnitrope SurePal 10 10mg/1.5ml solution for injection cartridges
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Omnitrope SurePal 15 15mg/1.5ml solution for injection cartridges
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Omnitrope SurePal 5 5mg/1.5ml solution for injection cartridges
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Growth hormone deficiency |
Tetracosactide
Tetracosactide 250micrograms/1ml solution for injection ampoules
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Primary adrenal insufficiency (Addison’s disease) |